China green-lights domestic Ebola shot for clinical trials

China has approved a locally developed Ebola vaccine from its Academy of Military Medical Sciences for clinical trials, state news agency Xinhua said Thursday, according to Reuters. Media reports say the trial could start later this month, which would make the vaccine the third Ebola shot tested in humans behind candidates from GlaxoSmithKline ($GSK) and Merck ($MRK)/NewLink Genetics ($NLNK). More

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.